Clincosm LogoSign in Get a demo

HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis

Sponsor
Changhai Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01847248
Collaborator
(none)
118
Enrollment
1
Location
29
Duration (Months)
4.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

  • Molecules indicating endothelial injury may serve as biomarkers for severe sepsis because of the critical role of endothelial injury in organ dysfunction during severe sepsis.

  • HSPA12B is primarily located in endothelial cells and detectable during sepsis.

  • The investigators speculated that HSPA12B from endothelial cells might be correlated with severe sepsis.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    118 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Study Start Date :
    May 1, 2011
    Actual Primary Completion Date :
    Mar 1, 2013
    Actual Study Completion Date :
    Oct 1, 2013

    Arms and Interventions

    Arm Intervention/Treatment
    sepsis

    Patients with sepsis but not severe sepsis
    Severe sepsis

    Patients with severe sepsis
    SIRS

    Patients with SIRS after major orthopedics surgery
    Control

    Healthy volunteers

    Outcome Measures

    Primary Outcome Measures

    1. 28-day mortality [28 days]

      mortality within 28 days after recruitment.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Adult patients

    • Patients meet the diagnostic criteria according to the grouping

    Exclusion Criteria:

    • patients without informed consent

    • patients who were undergoing continuous renal replacement therapy before sampling

    • patients with special infection induced by virus, tubercle bacillus, mycoplasma, Chlamydia, and so on

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital Shanghai China 200433

    Sponsors and Collaborators

    • Changhai Hospital

    Investigators

    • Principal Investigator: Ke-ming Zhu, M.D., Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jia-feng Wang, Dr., Changhai Hospital
    ClinicalTrials.gov Identifier:
    NCT01847248
    Other Study ID Numbers:
    • HSPA12B-sepsis-biomarker
    First Posted:
    May 6, 2013
    Last Update Posted:
    Nov 25, 2013
    Last Verified:
    Nov 1, 2013
    Keywords provided by Jia-feng Wang, Dr., Changhai Hospital
    sepsis
    biomarker
    HSPA12B
    Additional relevant MeSH terms:
    Sepsis
    Toxemia

    Study Results

    No Results Posted as of Nov 25, 2013